Latest Conference Coverage


Reisa Sperling, MD: Advances in Early Detection of Alzheimer Disease

Reisa Sperling, MD: Advances in Early Detection of Alzheimer Disease

October 17th 2019

Sperling sat down with NeurologyLive at AAIC 2019 to discuss her thoughts on efforts to detect and treat Alzheimer early on in the disease.


Marie D'hooghe, MD, PhD: Pregnancy Plans for Patients With MS

Marie D'hooghe, MD, PhD: Pregnancy Plans for Patients With MS

October 4th 2019

The neurologist at the National MS Center and University Hospital, in Brussels, discussed the clinician mindset when treating women with MS who plan to get pregnant, and how patients using assistive reproductive treatments should be approached.


RimabotulinumtoxinB Has Rapid, Long-Lasting Treatment Effect in Sialorrhea

RimabotulinumtoxinB Has Rapid, Long-Lasting Treatment Effect in Sialorrhea

October 1st 2019

The drug, the only approved botulinum toxin type B on the market, was recently approved for the treatment of chronic sialorrhea in adults.


Jan Hillert, MD, PhD: Stem Cell Transplants in MS

Jan Hillert, MD, PhD: Stem Cell Transplants in MS

September 30th 2019

The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet spoke to the use of stem cell transplantation as a potential method of treating multiple sclerosis.


Mitsubishi Tanabe Reveals Phase 3 Study for Continuous Carbidopa/Levodopa in Parkinson Disease

Mitsubishi Tanabe Reveals Phase 3 Study for Continuous Carbidopa/Levodopa in Parkinson Disease

September 26th 2019

The clinical development of ND0612 includes 2 doses; a low dose for mid-stage Parkinson patients experiencing loss of motor control on oral therapy, and a high dose for severe disease in which oral drugs are no longer effective.


Inhaled Levodopa Holds Off Dyskinesia in Parkinson Disease

Inhaled Levodopa Holds Off Dyskinesia in Parkinson Disease

September 26th 2019

Acorda Therapeutics’ Inbrija, an inhalation powder formulation of levodopa, was associated with no significant increases in troublesome dyskinesia for patients being treated with carbidopa/levodopa.


Amantadine ER Capsules for Dyskinesia Show Consistent Safety, Improved Motor Skills

Amantadine ER Capsules for Dyskinesia Show Consistent Safety, Improved Motor Skills

September 25th 2019

Data of amantadine (Gocovri, Adamas) extended-release tablets suggested that the therapy is, in fact, safe and tolerable with a unique pharmacokinetic profile, and results in significant improvements in dyskinesia for patients with Parkinson disease.


Pimavanserin Improves Parkinson Disease Depressive Symptoms

Pimavanserin Improves Parkinson Disease Depressive Symptoms

September 25th 2019

Acadia Pharmaceuticals’ pimavanserin significantly improved Hamilton Depression Rating Scale scores for patients with Parkinson disease with depressive symptoms in an 8-week, open-label study.


Tavapadon Posts Positive Phase 2 Results in Early Parkinson Disease

Tavapadon Posts Positive Phase 2 Results in Early Parkinson Disease

September 24th 2019

Cerevel Therapeutics’ highly selective dopamine D1/D5 agonist showed significant reductions in UPDRS-III scores for those with early-stage Parkinson disease and is planned to enter phase 3 in 2020.


Danielle Andrade, MD, MSc: Communicating and Network Building in Epilepsy Care

Danielle Andrade, MD, MSc: Communicating and Network Building in Epilepsy Care

September 24th 2019

The professor of medicine, neurology, at the University of Toronto shared insight into the importance of communication and a good network of physicians to an adult neurologist caring for patients with epilepsy.


Marie D'hooghe, MD, PhD: Treating Multiple Sclerosis During Pregnancy

Marie D'hooghe, MD, PhD: Treating Multiple Sclerosis During Pregnancy

September 20th 2019

The neurologist at the National MS Center and University Hospital, in Brussels, spoke to the decision-making process when treating women with MS who seek to get pregnant, or who are planning a family.


Danielle Andrade, MD, MSc: Education for Adult Neurologists on Pediatric-Onset Epilepsies

Danielle Andrade, MD, MSc: Education for Adult Neurologists on Pediatric-Onset Epilepsies

September 19th 2019

The professor of medicine, neurology, at the University of Toronto discussed the best ways for adult neurologists to ensure a smooth transition of care for patients with epilepsy entering their care.


Jan Hillert, MD, PhD: The Blood-Brain Barrier in Multiple Sclerosis

Jan Hillert, MD, PhD: The Blood-Brain Barrier in Multiple Sclerosis

September 19th 2019

The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet discussed the evolving understanding of the blood-brain barrier in MS, and what might still be left to uncover.


Achthar Gel Associated With Lower Cost Per Response in Multiple Sclerosis Relapse

Achthar Gel Associated With Lower Cost Per Response in Multiple Sclerosis Relapse

September 18th 2019

Mallinckrodt’s repository corticotropin injection was shown to have a lower cost per patient response compared to other late-line treatments for multiple sclerosis relapses, costing an estimated $148,528 less per response.


Danielle Andrade, MD, MSc: Ensuring Smooth Transitions to Adult Epilepsy Care

Danielle Andrade, MD, MSc: Ensuring Smooth Transitions to Adult Epilepsy Care

September 18th 2019

The professor of medicine, neurology, at the University of Toronto discussed the best ways for pediatric neurologists to ensure a smooth transition of care for patients with epilepsy who are leaving the pediatric system.


MS Treatment Temelimab (GNbAC1) Shows Sustained 96-Week Efficacy

MS Treatment Temelimab (GNbAC1) Shows Sustained 96-Week Efficacy

September 17th 2019

The GeNeuro agent showed marked reductions in brain atrophy in the thalamus and cerebral cortex through a long-term extension period treating patients with multiple sclerosis.


R. Edward Hogan, MD: Clinician Takeaways for Using Diazepam Nasal Spray

R. Edward Hogan, MD: Clinician Takeaways for Using Diazepam Nasal Spray

September 17th 2019

The director of the adult epilepsy center at Washington University in St. Louis discussed the takeaways for clinicians regarding the use of intranasal diazepam as a treatment for runs of seizures in patients with refractory epilepsy.


Jan Hillert, MD, PhD: Treating the Non-Inflammatory Aspects of MS

Jan Hillert, MD, PhD: Treating the Non-Inflammatory Aspects of MS

September 16th 2019

The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet spoke to the aspects of MS—such as brain volume loss—which are not currently being addressed by the available disease-modifying therapies.


Relapsing MS Treatment With Natalizumab Linked to High NEDA Rate Over 4 Years

Relapsing MS Treatment With Natalizumab Linked to High NEDA Rate Over 4 Years

September 16th 2019

According to new data from STRIVE, 75.4% of those treated with natalizumab achieved overall No Evidence of Disease Activity status by year 4, and no patients had incidence of progressive multifocal leukoencephalopathy.


Siponimod Delays Time to Wheelchair Use in Secondary Progressive MS

Siponimod Delays Time to Wheelchair Use in Secondary Progressive MS

September 13th 2019

After showing significant benefits in delayed disease progression in patients with secondary progressive MS, new data suggests siponimod can delay the time to wheelchair dependence by 4 years.


Ocrelizumab Reduces MS Disease Activity in Patients With Prior DMT Failure

Ocrelizumab Reduces MS Disease Activity in Patients With Prior DMT Failure

September 13th 2019

Nearly 87% of patients enrolled in the phase 3b CASTING study had no evidence of disease activity following treatment with ocrelizumab after having an inadequate response to prior DMTs.


Ocrelizumab Is Beneficial Across Long-Term Multiple Sclerosis Outcomes

Ocrelizumab Is Beneficial Across Long-Term Multiple Sclerosis Outcomes

September 13th 2019

The global head of neuroimmunology at Genentech spoke about the wealth of data being presented on its anti-CD20 monoclonal antibody ocrelizumab, as well as the success thus far in trials of its NMOSD agent, satralizumab.


Satralizumab's Efficacy in NMOSD Boosts the Case for IL-6 Inhibition

Satralizumab's Efficacy in NMOSD Boosts the Case for IL-6 Inhibition

September 12th 2019

Study coauthor and professor of neurology and ophthalmology at the University of Colorado provides insight into phase 3 study results of satralizumab, presented at ECTRIMS 2019.


Alberto Ascherio, MD, DrPH: Using Vitamin D to Treat MS

Alberto Ascherio, MD, DrPH: Using Vitamin D to Treat MS

September 12th 2019

The professor of epidemiology and nutrition at Harvard TH Chan School of Public Health discussed what might be an optimal dose of vitamin D supplementation in MS, and how vitamin D deficiency should be addressed as a modifiable risk factor.


Ponesimod Superior to Teriflunomide in Lowering MS Relapse Rates

Ponesimod Superior to Teriflunomide in Lowering MS Relapse Rates

September 12th 2019

New phase 3 data from the OPTIMUM head-to-head trial show that 20-mg ponesimod resulted in a significantly lower annualized relapse rate in adults with multiple sclerosis compared to 14-mg teriflunomide at 108 weeks.


Dimethyl Fumarate Treatment Maintains Low MS Relapse Rates Long-Term

Dimethyl Fumarate Treatment Maintains Low MS Relapse Rates Long-Term

September 11th 2019

New decade-long data have suggested that multiple sclerosis treatment with dimethyl fumarate is associated with stable EDSS scores ≤3, and a low number of patients with confirmed disability progression.


Danielle Andrade, MD, MSc: Coordinating Epilepsy Care Transition Between Physicians

Danielle Andrade, MD, MSc: Coordinating Epilepsy Care Transition Between Physicians

September 11th 2019

The professor of medicine, neurology, at the University of Toronto discussed the need for physicians to work together while transitioning patients with epilepsy—who may have any number of comorbidities—from pediatric care to adult care.


Bruce Cree, MD, PhD, MAS: Exploring Clinical Utility of Siponimod, Fingolimod in MS

Bruce Cree, MD, PhD, MAS: Exploring Clinical Utility of Siponimod, Fingolimod in MS

September 11th 2019

The clinical research director of the UCSF Multiple Sclerosis Center discusses recent data on siponimod and its impact on cognitive measures in patients with secondary progressive MS, as well as results of the 3-arm ASSESS study comparing low-dose fingolimod and glatiramer acetate.


Ocrelizumab Analyses of Neurofilament Light Levels Reveals Disease Progression Insights

Ocrelizumab Analyses of Neurofilament Light Levels Reveals Disease Progression Insights

September 11th 2019

New data from clinical trials of ocrelizumab showed that the anti-CD20+ B cell therapy lowered serum NfL levels, and that the NfL levels offered prognostic value for disease progression in MS.

© 2024 MJH Life Sciences

All rights reserved.